{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T08:18:37Z","timestamp":1760170717476,"version":"build-2065373602"},"reference-count":35,"publisher":"MDPI AG","issue":"22","license":[{"start":{"date-parts":[[2021,11,10]],"date-time":"2021-11-10T00:00:00Z","timestamp":1636502400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007632","name":"Changhua Christian Hospital","doi-asserted-by":"publisher","award":["109-CCH-IRP-008 , 109-CCH-IRP-088 and 110-CCH-IRP-020"],"award-info":[{"award-number":["109-CCH-IRP-008 , 109-CCH-IRP-088 and 110-CCH-IRP-020"]}],"id":[{"id":"10.13039\/501100007632","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: Glecaprevir\/pibrentasvir is a protease inhibitor-containing pangenotypic direct-acting antiviral regimen that has been approved for the treatment of chronic hepatitis C. The present study aimed to evaluate the safety and efficacy of glecaprevir\/pibrentasvir in patients with compensated cirrhosis in a real-world setting. Methods: We evaluated the real-world safety and efficacy of glecaprevir\/pibrentasvir in patients with compensated cirrhosis from five hospitals in the Changhua Christian Care System, who underwent treatment between August 2018 and October 2020. The primary endpoint was a sustained virological response observed 12 weeks after completion of the treatment. Results: Ninety patients, including 70 patients who received the 12-week therapy and 20 patients who received the 8-week therapy, were enrolled. The mean age of the patients was 65 years, and 57.8% of the patients were males. Sixteen (17.8%) patients had end-stage renal disease, and 15 (16.7%) had co-existing hepatoma. The hepatitis C virus genotypes 1 (40%) and 2 (35.6%) were most common. The common side effects included anorexia (12.2%), pruritus (7.8%), abdominal discomfort (7.8%), and malaise (7.8%). Laboratory adverse grade \u22653 events included anemia (6.3%), thrombocytopenia (5.1%), and jaundice (2.2%). The overall sustained virological response rates were 94.4% and 97.7% in the intention-to-treat and per-protocol analyses, respectively. Conclusions: the glecaprevir\/pibrentasvir treatment regimen was highly effective and well tolerated among patients with compensated cirrhosis in the real-world setting.<\/jats:p>","DOI":"10.3390\/jcm10225236","type":"journal-article","created":{"date-parts":[[2021,11,11]],"date-time":"2021-11-11T23:02:41Z","timestamp":1636671761000},"page":"5236","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Real-World Experience of Chronic Hepatitis C-Related Compensated Liver Cirrhosis Treated with Glecaprevir\/Pibrentasvir: A Multicenter Retrospective Study"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6860-1051","authenticated-orcid":false,"given":"Pei-Yuan","family":"Su","sequence":"first","affiliation":[{"name":"Division of Gastroenterology, Department of Internal Medicine, Changhua Christian Hospital, Changhua 500, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang-Yuan","family":"Chen","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Internal Medicine, Changhua Christian Hospital, Changhua 500, Taiwan"},{"name":"Division of Gastroenterology, Department of Internal Medicine, Yuanlin Christian Hospital, Changhua 500, Taiwan"},{"name":"Department of Hospitality, MingDao University, Changhua 500, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun-Hung","family":"Lai","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Internal Medicine, Erhlin Christian Hospital, Changhua 500, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hung-Ming","family":"Chen","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Internal Medicine, Yunlin Christian Hospital, Yunlin 648, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chih-Ta","family":"Yao","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Internal Medicine, Lukang Christian Hospital, Changhua 500, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I-Ling","family":"Liu","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Internal Medicine, Changhua Christian Hospital, Changhua 500, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ya-Huei","family":"Zeng","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Internal Medicine, Changhua Christian Hospital, Changhua 500, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1021-2114","authenticated-orcid":false,"given":"Siou-Ping","family":"Huang","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Internal Medicine, Changhua Christian Hospital, Changhua 500, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0714-2250","authenticated-orcid":false,"given":"Yu-Chun","family":"Hsu","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Internal Medicine, Changhua Christian Hospital, Changhua 500, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shun-Sheng","family":"Wu","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Internal Medicine, Changhua Christian Hospital, Changhua 500, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fu-Yuan","family":"Siao","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine, Changhua Christian Hospital, Changhua 500, Taiwan"},{"name":"Department of Kinesiology, Health and Leisure, Chienkuo Technology University, Changhua 500, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3494-2245","authenticated-orcid":false,"given":"Hsu-Heng","family":"Yen","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Internal Medicine, Changhua Christian Hospital, Changhua 500, Taiwan"},{"name":"Artificial Intelligence Development Center, Changhua Christian Hospital, Changhua 500, Taiwan"},{"name":"General Education Center, Chienkuo Technology University, Changhua 500, Taiwan"},{"name":"Department of Electrical Engineering, Chung Yuan University, Taoyuan 320, Taiwan"},{"name":"College of Medicine, National Chung Hsing University, Taichung 400, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,11,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1186\/s12876-021-01792-8","article-title":"Retrieval of lost patients in the system for hepatitis C microelimination: A single-center retrospective study","volume":"21","author":"Yen","year":"2021","journal-title":"BMC Gastroenterol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.kjms.2016.06.002","article-title":"Rapid virological response assessment by Abbott RealTime hepatitis C virus assay for predicting sustained virological responses in patients with hepatitis C virus genotype 1 treated with pegylated-interferon and ribavirin","volume":"32","author":"Su","year":"2016","journal-title":"Kaohsiung J. Med. Sci."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"5084","DOI":"10.3748\/wjg.v18.i36.5084","article-title":"Decreased mitochondrial deoxyribonucleic acid and increased oxidative damage in chronic hepatitis C","volume":"18","author":"Yen","year":"2012","journal-title":"World J. Gastroenterol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"101596","DOI":"10.1016\/j.clinre.2020.101596","article-title":"Epidemiology of hepatitis C virus infection","volume":"45","year":"2021","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"729","DOI":"10.7326\/0003-4819-159-11-201312030-00005","article-title":"Pegylated interferon-alpha2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 1 receiving hemodialysis: A randomized trial","volume":"159","author":"Liu","year":"2013","journal-title":"Ann. Intern. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/S1473-3099(19)30073-8","article-title":"Eliminating hepatitis C","volume":"19","author":"Burki","year":"2019","journal-title":"Lancet Infect. Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/j.jfma.2019.06.014","article-title":"Real-world effectiveness and safety of glecaprevir\/pibrentasvir in Asian patients with chronic hepatitis C","volume":"118","author":"Hsu","year":"2019","journal-title":"J. Formos. Med. Assoc."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.12998\/wjcc.v7.i11.1270","article-title":"Anti-hepatitis C virus therapy in chronic kidney disease patients improves long-term renal and patient survivals","volume":"7","author":"Chen","year":"2019","journal-title":"World J. Clin. Cases"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Su, P.Y., Chen, Y.Y., Yen, H.H., Huang, S.P., Liu, I.L., Zeng, Y.H., Hsu, Y.C., and Siao, F.Y. (2021). Strategy for the Micro-Elimination of Hepatitis C among Patients with Diabetes Mellitus-A Hospital-Based Experience. J. Clin. Med., 10.","DOI":"10.3390\/jcm10112509"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Yen, H.H., Su, P.Y., Huang, S.P., Wu, L., Hsu, T.C., Zeng, Y.H., and Chen, Y.Y. (2021). Evaluation of non-alcoholic fatty liver disease in patients with inflammatory bowel disease using controlled attenuation parameter technology: A Taiwanese retrospective cohort study. PLoS ONE, 16.","DOI":"10.1371\/journal.pone.0252286"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.jhep.2019.10.020","article-title":"Glecaprevir\/pibrentasvir for 8weeks in treatment-naive patients with chronic HCV genotypes 1-6 and compensated cirrhosis: The EXPEDITION-8 trial","volume":"72","author":"Brown","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1056\/NEJMoa1704053","article-title":"Glecaprevir and Pibrentasvir in Patients with HCV and Severe Renal Impairment","volume":"377","author":"Gane","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1111\/jvh.13265","article-title":"Glecaprevir\/pibrentasvir for patients with chronic hepatitis C virus infection and severe renal impairment","volume":"27","author":"Liu","year":"2020","journal-title":"J. Viral Hepat."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/S1473-3099(17)30496-6","article-title":"Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): A single-arm, open-label, multicentre phase 3 trial","volume":"17","author":"Forns","year":"2017","journal-title":"Lancet Infect. Dis."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1016\/j.jhep.2020.01.025","article-title":"Real-world effectiveness and safety of glecaprevir\/pibrentasvir for the treatment of patients with chronic HCV infection: A meta-analysis","volume":"72","author":"Lampertico","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1111\/apt.15222","article-title":"Real-world effectiveness and safety of glecaprevir\/pibrentasvir for the treatment of chronic hepatitis C infection: Data from the German Hepatitis C-Registry","volume":"49","author":"Berg","year":"2019","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1007\/s40846-021-00608-0","article-title":"Performance Comparison of the Deep Learning and the Human Endoscopist for Bleeding Peptic Ulcer Disease","volume":"41","author":"Yen","year":"2021","journal-title":"J. Med. Biol. Eng."},{"key":"ref_18","unstructured":"European Association for the Study of the Liver, Clinical Practice Guidelines Panel: Chair (2020). EASL recommendations on treatment of hepatitis C: Final update of the series. J. Hepatol., 73, 1170\u20131218."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1007\/s12325-020-01301-5","article-title":"Effectiveness of 8-Week Glecaprevir\/Pibrentasvir for Treatment-Naive, Compensated Cirrhotic Patients with Chronic Hepatitis C Infection","volume":"37","author":"Flamm","year":"2020","journal-title":"Adv. Ther."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1093\/cid\/ciz022","article-title":"Safety and Pharmacokinetics of Glecaprevir\/Pibrentasvir in Adults With Chronic Genotype 1-6 Hepatitis C Virus Infections and Compensated Liver Disease","volume":"69","author":"Gane","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Yen, H.H., Su, P.Y., Zeng, Y.H., Liu, I.L., Huang, S.P., Hsu, Y.C., Chen, Y.Y., Yang, C.W., Wu, S.S., and Chou, K.C. (2020). Glecaprevir-pibrentasvir for chronic hepatitis C: Comparing treatment effect in patients with and without end-stage renal disease in a real-world setting. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0237582"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e10944","DOI":"10.7717\/peerj.10944","article-title":"Direct-acting antiviral treatment for Hepatitis C Virus in geriatric patients: A real-world retrospective comparison between early and late elderly patients","volume":"9","author":"Yen","year":"2021","journal-title":"PeerJ"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.jhep.2019.04.017","article-title":"Sustained virologic response to direct-acting antiviral therapy in patients with chronic hepatitis C and hepatocellular carcinoma: A systematic review and meta-analysis","volume":"71","author":"Ji","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Klinker, H., Naumann, U., R\u00f6ssle, M., Berg, T., Bondin, M., Lohmann, K., Koenig, B., Zeuzem, S., and Cornberg, M. (2021). Glecaprevir\/pibrentasvir for 8 weeks in patients with compensated cirrhosis: Safety and effectiveness data from the German Hepatitis C-Registry. Liver Int.","DOI":"10.1111\/liv.14937"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1002\/hep.29541","article-title":"Glecaprevir\/pibrentasvir for hepatitis C virus genotype 3 patients with cirrhosis and\/or prior treatment experience: A partially randomized phase 3 clinical trial","volume":"67","author":"Wyles","year":"2018","journal-title":"Hepatology"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1093\/cid\/ciy585","article-title":"Hepatitis C Guidance 2018 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection","volume":"67","author":"Panel","year":"2018","journal-title":"Clin. Infect. Dis."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1002\/hep.31060","article-title":"Hepatitis C Guidance 2019 Update: American Association for the Study of Liver Diseases-Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection","volume":"71","author":"Ghany","year":"2020","journal-title":"Hepatology"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"99","DOI":"10.3892\/etm.2020.9531","article-title":"Dynamics of APRI and FIB-4 in HCV cirrhotic patients who achieved SVR after DAA therapy","volume":"21","author":"Leustean","year":"2021","journal-title":"Exp. Ther. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1111\/jvh.13280","article-title":"Dynamics of liver stiffness by transient elastography in patients with chronic hepatitis C virus infection receiving direct-acting antiviral therapy-Results from the German Hepatitis C-Registry","volume":"27","author":"Knop","year":"2020","journal-title":"J. Viral Hepat."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Rosato, V., Ascione, A., Nevola, R., Fracanzani, A.L., Piai, G., Messina, V., Claar, E., Coppola, C., Fontanella, L., and Lombardi, R. (2021). Factors affecting long-term changes of liver stiffness in direct-acting anti-hepatitis C virus therapy: A multicentre prospective study. J. Viral Hepat.","DOI":"10.1111\/jvh.13617"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jhep.2018.02.015","article-title":"Hepatitis C virus eradication by direct-acting antiviral agents improves carotid atherosclerosis in patients with severe liver fibrosis","volume":"69","author":"Petta","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1186\/s12967-019-2033-x","article-title":"Incidence and risk factors of early HCC occurrence in HCV patients treated with direct acting antivirals: A prospective multicentre study","volume":"17","author":"Rinaldi","year":"2019","journal-title":"J. Transl. Med."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Rinaldi, L., Nevola, R., Franci, G., Perrella, A., Corvino, G., Marrone, A., Berretta, M., Morone, M.V., Galdiero, M., and Giordano, M. (2020). Risk of Hepatocellular Carcinoma after HCV Clearance by Direct-Acting Antivirals Treatment Predictive Factors and Role of Epigenetics. Cancers, 12.","DOI":"10.3390\/cancers12061351"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.atherosclerosis.2020.01.010","article-title":"Impact of hepatitis C virus clearance by direct-acting antiviral treatment on the incidence of major cardiovascular events: A prospective multicentre study","volume":"296","author":"Adinolfi","year":"2020","journal-title":"Atherosclerosis"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1111\/dom.14168","article-title":"Reduced incidence of type 2 diabetes in patients with chronic hepatitis C virus infection cleared by direct-acting antiviral therapy: A prospective study","volume":"22","author":"Adinolfi","year":"2020","journal-title":"Diabetes Obes. Metab."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/10\/22\/5236\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:28:19Z","timestamp":1760167699000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/10\/22\/5236"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,10]]},"references-count":35,"journal-issue":{"issue":"22","published-online":{"date-parts":[[2021,11]]}},"alternative-id":["jcm10225236"],"URL":"https:\/\/doi.org\/10.3390\/jcm10225236","relation":{},"ISSN":["2077-0383"],"issn-type":[{"type":"electronic","value":"2077-0383"}],"subject":[],"published":{"date-parts":[[2021,11,10]]}}}